Rapamycin (Sirolimus) Hair and Skin Changes: What Patients and Clinicians Need to Know

What skin effects are established for oral sirolimus?

The current DailyMed oral sirolimus label lists acne among the most common adverse reactions in the lymphangioleiomyomatosis study. In a renal-transplant study, acne occurred in 22% of both sirolimus dose groups and 19% of the placebo group; rash occurred in 10% of the 2 mg/day group, 20% of the 5 mg/day group, and 6% of placebo. Everyone in that study also received cyclosporine and corticosteroids, so those percentages are not a clean estimate for sirolimus used alone 1.

This context is important. A statement such as “rapamycin causes acne in 20% of users” removes the indication, dose, comparator, and other immunosuppressive drugs that produced the number.

Acneiform eruptions and rash

Sirolimus-associated eruptions may look acne-like, follicular, or more broadly inflammatory. A published report described two renal-transplant recipients with severe acneiform eruptions that resolved only after sirolimus was discontinued 2. Case reports can establish that an event is possible, but they cannot establish how often it occurs.

An observational study performed systematic skin, mucosal, nail, and hair examinations in 80 renal-transplant recipients receiving sirolimus-based therapy. Cutaneous findings were common, including acne-like eruptions, scalp folliculitis, edema, aphthous ulcers, and nail disorders 3. Most participants also received mycophenolate and corticosteroids, which again limits direct extrapolation to other populations.

New rash deserves assessment because appearance alone cannot reliably distinguish an acneiform drug eruption from infection, allergy, or another dermatosis. Rapidly spreading rash, blistering, facial swelling, breathing difficulty, or mucosal involvement requires urgent evaluation.

Does rapamycin cause hair loss?

Hair thinning or shedding is reported by some people using sirolimus, and hair was included in published transplant dermatology assessments. However, the current U.S. oral sirolimus label does not list a controlled-trial alopecia percentage, and the available literature does not support a universal “16%” rate for all users.

Several factors make attribution difficult:

• transplant recipients often take multiple medicines that can affect hair;
• illness, surgery, nutritional changes, thyroid disease, iron deficiency, and stress can trigger telogen effluvium;
• dose and sirolimus blood exposure vary substantially by indication and interacting drugs; and
• intermittent off-label regimens have not been studied with the same depth as transplant regimens.

A useful evaluation documents when shedding started, other medication changes, recent illness or surgery, scalp symptoms, and whether loss is diffuse or patchy. The prescriber may consider examination, laboratory evaluation, or dermatology referral based on that history. Evidence does not support promising a fixed three-to-six-month recovery timeline.

Wound healing and surgery

Impaired or delayed wound healing is an explicit warning in the oral sirolimus label. Reported complications include lymphocele and wound dehiscence, and the label notes that mTOR inhibitors can affect growth-factor production, angiogenesis, fibroblast proliferation, and vascular permeability 1.

A systematic review of 37 randomized trials found higher odds of wound complications and lymphoceles in several transplant regimens containing mTOR inhibitors 4. A smaller retrospective study of dermatologic surgery, however, did not find a statistically significant increase in complications and emphasized its limited sample size 5.

Those findings do not produce a universal instruction to stop sirolimus seven days, two weeks, or four weeks before every procedure. The decision depends on why sirolimus is prescribed, the procedure, wound risk, drug exposure, and the danger of interrupting immunosuppression. Transplant patients should never stop it without the transplant team.

Mouth sores are related but not the same as skin disease

Stomatitis is a common labeled adverse reaction in oral sirolimus studies 1. Mouth ulcers can impair eating or resemble infection, so persistent, severe, or recurrent lesions should be reported to the prescriber.

The previous version of this page gave a fixed topical-steroid regimen and trough-level target. Those instructions were not established by the cited study and have been removed. Treatment depends on severity, infection risk, indication, and the rest of the immunosuppressive regimen.

Drug interactions can change sirolimus exposure

Sirolimus is a substrate of CYP3A4 and P-glycoprotein. The current label says to avoid strong inhibitors such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin, and strong inducers such as rifampin or rifabutin. Grapefruit juice must not be used with sirolimus 1.

The label provides measured examples: ketoconazole increased sirolimus exposure (AUC) 10.9-fold, erythromycin increased AUC 4.2-fold, and rifampin reduced AUC by about 82%. These are pharmacokinetic interaction data. By contrast, it is not defensible to assign every skin symptom to a specific blood concentration or prescribe an unofficial trough target for longevity use.

What does the PEARL longevity trial show?

PEARL was a 48-week decentralized, double-blind, randomized, placebo-controlled trial in generally healthy, normally aging adults. Participants received placebo, 5 mg compounded rapamycin weekly, or 10 mg weekly. Overall adverse and serious adverse events were similar across groups 6.

That is more informative than anecdotes, but it does not prove long-term dermatologic safety or establish that low-dose rapamycin prevents skin aging. The trial's primary outcome was visceral adiposity; hair loss and specific dermatologic events were not the primary endpoint. The study authors were employees and shareholders of the company sponsoring or conducting the work, a relevant limitation disclosed in the PubMed record.

The previous page incorrectly described PEARL as an eight-week 2024 trial with daily 1 mg and 2 mg arms. The published trial was released in 2025, lasted 48 weeks, and tested weekly 5 mg and 10 mg regimens.

Does rapamycin improve skin aging?

Mechanistic research on mTOR, autophagy, and cellular senescence is not equivalent to evidence that oral sirolimus improves wrinkles, elasticity, pigmentation, or other cosmetic outcomes. PEARL did not establish a cosmetic skin benefit. Oral sirolimus is not FDA approved for anti-aging or cosmetic skin treatment.

Topical sirolimus is a separate product and evidence base

HYFTOR is an FDA-approved 0.2% sirolimus gel for facial angiofibroma associated with tuberous sclerosis in adults and children 6 years and older. Its label directs application to affected facial skin twice daily within age-based maximum daily amounts 7.

HYFTOR should not be described as an ointment, and its approval does not establish compounded topical sirolimus as a general skin-rejuvenation treatment. In the 104-week open-label HYFTOR safety trial, application-site irritation, dry skin, and acne were among the most common local reactions 7.

A practical response to hair or skin changes

1. Do not stop transplant therapy independently. Interruption can risk rejection.
2. Record the timeline. Note sirolimus start or dose changes, new interacting medicines, illness, surgery, and symptom onset.
3. Check the medication list for exposure-changing interactions. Include antibiotics, antifungals, seizure medicines, cannabidiol, grapefruit, and St. John's wort.
4. Describe the finding precisely. Acne-like bumps, diffuse shedding, patchy loss, mouth ulcers, a nonhealing wound, and a blistering rash require different evaluations.
5. Escalate urgent features. Facial swelling, breathing trouble, extensive blistering, fever with rash, wound opening, drainage, or signs of infection should be assessed promptly.